ReviewNature reviews. Nephrology2024
The impact of population ageing on the burden of chronic kidney disease.
Review in Nature reviews. Nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Comprehensive geriatric assessment and optimisation in advanced chronic kidney disease: a systematic review and narrative synthesis examining clinical outcomes and decision-making.BMC nephrology · 2026Pooled it
- Cancer-related mortality among solid organ transplant recipients: systematic review and meta-analysis.Frontiers in transplantation · 2026Pooled it
- Comparison of Drug-Coated Balloon versus Plain Balloon Angioplasty for the Treatment of Arteriovenous Fistula Stenosis: A systematic review and meta-analysis of randomized controlled trials.Cardiovascular and interventional radiology · 2026Pooled it
- Enhancing treatment adherence in dialysis patients through digital health interventions: a systematic review and meta-analysis of randomized controlled trials.Renal failure · 2025Pooled it
- Therapeutic Efficacy of Autologous Blood-Derived Stem Cells with Growth Factors in Moderate to Severe Alzheimer's Disease: A Clinical Trial.Molecular neurobiology · 2025Trial
- The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial.BMC nephrology · 2025Trial
- Article
- Predictors of Early Posttransplant Complications and Clinical Outcomes in Kidney Transplant Recipients Aged ≥65 y.Transplantation direct · 2026Article
- Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark.Kidney medicine · 2026Article
- The updated global burden of chronic kidney disease: one death every 20 seconds.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.Chinese medicine · 2026Review
- Mortality trends involving chronic kidney disease and electrolyte and acid-base disorders in the United States, 1999-2023: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Article
- Comprehensive geriatric assessment in nephrology and the importance of fidelity: what the GOAL trial really tells us.Clinical kidney journal · 2026Article
- Article
- Article
- Article
- Wearable Electronics for Precision Diagnosis Through Advanced Manufacturing and Integration.Nano-micro letters · 2026Review
- Dose-dependent association of depression with incidence of end-stage kidney disease and all-cause mortality, CKD-JAC study: a retrospective cohort study.Clinical and experimental nephrology · 2026Article
- Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies.Toxins · 2026Review
- Deciding between conservative kidney management and dialysis in older people with kidney failure: a narrative review.Clinical kidney journal · 2026Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of chronic kidney disease (CKD) and its risk factors are projected to rise in parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category G3-G5 may exceed 10% in some regions, resulting in substantial health and economic burdens that will disproportionately affect lower-income countries. The extent to which the CKD epidemic can be mitigated depends largely on the uptake of prevention efforts to address modifiable risk factors, the implementation of cost-effective screening programmes for early detection of CKD in high-risk individuals and widespread access and affordability of new-generation kidney-protective drugs to prevent the development and delay the progression of CKD. Older patients require a multidisciplinary integrated approach to manage their multimorbidity, polypharmacy, high rates of adverse outcomes, mental health, fatigue and other age-related symptoms. In those who progress to kidney failure, comprehensive conservative management should be offered as a viable option during the shared decision-making process to collaboratively determine a treatment approach that respects the values and wishes of the patient. Interventions that maintain or improve quality of life, including pain management and palliative care services when appropriate, should also be made available.
Indexed as
Identifiers
39025992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.